307 related articles for article (PubMed ID: 16644473)
1. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
2. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
3. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
[TBL] [Abstract][Full Text] [Related]
4. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
[TBL] [Abstract][Full Text] [Related]
5. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
[TBL] [Abstract][Full Text] [Related]
6. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
[TBL] [Abstract][Full Text] [Related]
7. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
Van Lier RA; Boot JH; De Groot ER; Aarden LA
Eur J Immunol; 1987 Nov; 17(11):1599-604. PubMed ID: 2960543
[TBL] [Abstract][Full Text] [Related]
8. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
Hirsch R; Gress RE; Pluznik DH; Eckhaus M; Bluestone JA
J Immunol; 1989 Feb; 142(3):737-43. PubMed ID: 2521507
[TBL] [Abstract][Full Text] [Related]
9. Expression of a 33-kDa antigen Tm 1 on lymphocyte surface after modulation of cell surface antigens by IgM monoclonal antibody.
Hara T; Jung LK; Fu SM
J Immunol; 1988 Feb; 140(4):1028-33. PubMed ID: 2963858
[TBL] [Abstract][Full Text] [Related]
10. Influence of MHC class I molecules on T-cell proliferation induced by CD3 or Thy-1 stimulation.
Amirayan N; Furrie E; Deleuil F; Mellor A; Leserman L; Machy P
Immunology; 1995 Sep; 86(1):71-8. PubMed ID: 7590885
[TBL] [Abstract][Full Text] [Related]
11. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex.
Ceuppens JL; Bloemmen FJ; Van Wauwe JP
J Immunol; 1985 Dec; 135(6):3882-6. PubMed ID: 2933454
[TBL] [Abstract][Full Text] [Related]
12. In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TcR signaling.
Flamand V; Donckier V; Abramowicz D; Goldman M; Vandenabeele P; Urbain J; Moser M; Leo O
Cell Immunol; 1994 Aug; 157(1):239-48. PubMed ID: 8039247
[TBL] [Abstract][Full Text] [Related]
13. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
14. T cell activation by anti-CD3 antibodies: function of Fc receptors on B cell blasts, but not resting B cells, and CD18 on the responding T cells.
Austyn JM; Smith KG; Morris PJ
Eur J Immunol; 1987 Sep; 17(9):1329-35. PubMed ID: 3498637
[TBL] [Abstract][Full Text] [Related]
15. A polymorphic Fc receptor for mouse IgG2b on human B cells and monocytes.
Holtrop S; Rijke-Schilder GP; Koene RA; Tax WJ
Immunology; 1991 Dec; 74(4):613-20. PubMed ID: 1838352
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2.
Lin J; Yon RW; Chavin KD; Qin L; Woodward J; Ding Y; Yagita H; Bromberg JS
Transplantation; 1995 Apr; 59(8):1162-71. PubMed ID: 7537394
[TBL] [Abstract][Full Text] [Related]
17. Temperature requirements and kinetics of T cell signaling. Velocity of triggering correlates with functional effects of anti-CD3 mAb.
Abdi K; Reed ML; Mentzer SJ; Herrmann SH
J Immunol; 1989 May; 142(9):2971-80. PubMed ID: 2468707
[TBL] [Abstract][Full Text] [Related]
18. In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth.
Hirsch R; Ellenhorn JD; Bluestone JA
Princess Takamatsu Symp; 1988; 19():237-43. PubMed ID: 2978618
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD3:anti-IL-2 receptor-bispecific mAb-mediated immunomodulation. Low systemic toxicity, differential effect on lymphoid tissue, and inhibition of cell-mediated hypersensitivity.
MacLean JA; Su Z; Colvin RB; Wong JT
J Immunol; 1995 Oct; 155(7):3674-82. PubMed ID: 7561068
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
